Nature Communications · 2020 · 100 citations · 45 references
Life SciencesBiotechnologyGeneticsGenetic EngineeringGenome EditingMolecular OncologyCrispr-based EngineeringCrispr-cas SystemsTherapeutic Genome EditingCancer Gene EditingCrispr-cas9 Genome EditingDoxycycline-inducible SystemsFunctional IntegrationGenome Editing In CellsIn Vivo Genome EditingNon-small Cell Lung Cancer TreatmentTransgenic Model Generation
The CRISPR-Cas9 system has increased the speed and precision of genetic editing in cells and animals. However, model generation for drug development is still expensive and time-consuming, demanding more target flexibility and faster turnaround times with high reproducibility. The generation of a tightly controlled ObLiGaRe doxycycline inducible SpCas9 (ODInCas9) transgene and its use in targeted ObLiGaRe results in functional integration into both human and mouse cells culminating in the generation of the ODInCas9 mouse. Genomic editing can be performed in cells of various tissue origins without any detectable gene editing in the absence of doxycycline. Somatic in vivo editing can model non-small cell lung cancer (NSCLC) adenocarcinomas, enabling treatment studies to validate the efficacy of candidate drugs. The ODInCas9 mouse allows robust and tunable genome editing granting flexibility, speed and uniformity at less cost, leading to high throughput and practical preclinical in vivo therapeutic testing.
45
Salmon provides fast and bias-aware quantification of transcript expression
Rob Patro, Geet Duggal, Michael I. Love et al. · Nature Methods · 2017 · 13.7K citations · Full text
Genome engineering using the CRISPR-Cas9 system
F. Ann Ran, Patrick D. Hsu, Jason Wright et al. · Nature Protocols · 2013 · 11.7K citations · Full text
Haoyi Wang, Hui Yang, Chikdu Shivalila et al. · Cell · 2013 · 3.6K citations · Full text
CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling
Randall J. Platt, Sidi Chen, Yang Zhou et al. · Cell · 2014 · 2.1K citations · Full text